What's next for the beaten-down ASX biotech stock? The post CSL shares crash to a 9-year low. Is it time to sell off my ...

Carlisle Companies' Q1 sales performance reflects macroeconomic weakness but also a transitory headwind from harsh winter ...

CSL is near decade lows. Can it ever climb back? The post Can the beaten-down CSL share price ever reach $300 again? appeared ...

Here's what the experts are tipping for the shares over the next 12 months. The post CSL, Resmed, Cochlear shares crash to ...

CSL ( (AU:CSL)) just unveiled an announcement. CSL Limited has continued its on-market share buy-back program, updating investors with a daily notification that as of 27 April 2026 it has repurchased ...

CSL Limited has reported the latest daily progress of its on-market share buy-back program for its ordinary fully paid shares. The company disclosed that it has repurchased a cumulative 5,550,945 ...

Investors looking for stocks in the Diversified Operations sector might want to consider either Marubeni Corp. (MARUY) or Carlisle (CSL). But which of these two stocks presents investors with the ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell short of the market’s revenue expectations in Q1 ...

Guinness Asset Management LTD has opened a new $10.3M position in $CSL, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 03-31-2025 ...

By Rajasik Mukherjee April 23 (Reuters) - Australian biotech giant CSL extended losses on Thursday, lingering near decade ...

Jonathan R. Collins, a director at $CSL, sold 1,050 shares of the company on 02-07-2025 for an estimated $366,702. We received data on the trade from a recent SEC ...